Double blind placebo controlled parallel group comparison of atomoxetine (Strattera) for generalized social anxiety disorder.

Trial Profile

Double blind placebo controlled parallel group comparison of atomoxetine (Strattera) for generalized social anxiety disorder.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Jun 2016

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Social phobia
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 14 Dec 2008 Primary endpoint changed from Liebowitz Social Anxiety Scale to Clinical Global Impressions Scale as reported by ClinicalTrials.gov.
    • 15 Sep 2008 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
    • 15 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top